Amin Khan - Feb 2, 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
Chief Scientific Officer
Signature
/s/ David Kennedy, Attorney-in-fact
Stock symbol
GRNA
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 06:27 PM
Next filing
Aug 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +277K 277K Feb 2, 2022 Common Stock 277K $1.23 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +256K 256K Feb 2, 2022 Common Stock 256K $1.23 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested or shall vest on March 25, 2022 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 25, 2023.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.